ACER Acer Therapeutics Inc

Price (delayed)

$0.75

Market cap

$12.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.43

Enterprise value

$13.98M

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four programs: ...

Highlights
Acer Therapeutics's debt has decreased by 3.9% QoQ
The company's quick ratio has shrunk by 63% QoQ and by 34% YoY
Acer Therapeutics's gross profit has shrunk by 60% YoY

Key stats

What are the main financial stats of ACER
Market
Shares outstanding
16.37M
Market cap
$12.28M
Enterprise value
$13.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
33.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.84
Earnings
Revenue
$360,000
EBIT
-$21.15M
EBITDA
-$21.08M
Free cash flow
-$23.43M
Per share
EPS
-$1.43
Free cash flow per share
-$1.46
Book value per share
-$0.77
Revenue per share
$0.02
TBVPS
$0.48
Balance sheet
Total assets
$15.32M
Total liabilities
$27.53M
Debt
$8.08M
Equity
-$12.21M
Working capital
-$13.49M
Liquidity
Debt to equity
-0.66
Current ratio
0.35
Quick ratio
0.31
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-5,854.4%
Gross margin
100%
Net margin
-5,909.3%
Operating margin
-6,603%
Efficiency
Return on assets
-80.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-5,874.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACER stock price

How has the Acer Therapeutics stock price performed over time
Intraday
-2.85%
1 week
11.94%
1 month
-64.95%
1 year
-74.83%
YTD
-70.12%
QTD
-70.12%

Financial performance

How have Acer Therapeutics's revenue and profit performed over time
Revenue
$360,000
Gross profit
$360,000
Operating income
-$23.77M
Net income
-$21.27M
Gross margin
100%
Net margin
-5,909.3%
Acer Therapeutics's gross profit has shrunk by 60% YoY
Acer Therapeutics's revenue has plunged by 60% YoY
The company's operating income fell by 34% YoY and by 9% QoQ
The company's net income fell by 24% YoY and by 9% QoQ

Growth

What is Acer Therapeutics's growth rate over time

Valuation

What is Acer Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
33.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
38.84
ACER's EPS is down by 13% YoY and by 6% from the previous quarter
Acer Therapeutics's equity has decreased by 39% from the previous quarter
Acer Therapeutics's revenue has plunged by 60% YoY
The price to sales (P/S) is 48% lower than the last 4 quarters average of 64.2

Efficiency

How efficient is Acer Therapeutics business performance
ACER's ROS has plunged by 199% YoY and by 9% from the previous quarter
Acer Therapeutics's return on assets has shrunk by 53% YoY and by 27% QoQ

Dividends

What is ACER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACER.

Financial health

How did Acer Therapeutics financials performed over time
Acer Therapeutics's total assets is 44% lower than its total liabilities
The company's quick ratio has shrunk by 63% QoQ and by 34% YoY
Acer Therapeutics's current ratio has shrunk by 60% QoQ and by 57% YoY
Acer Therapeutics's debt is 166% higher than its equity
Acer Therapeutics's equity has decreased by 39% from the previous quarter
Acer Therapeutics's debt to equity has increased by 31% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.